New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
09:36 EDTC, TSLA, NFLX, TWTR, GOOG, AAPL, WMT, MRKActive equity options trading on open
Active equity options trading on open according to Track Data: C AAPL NFLX MA MRK GOOG TSLA WMT TWTR
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 >>
September 21, 2015
11:14 EDTNFLXNetflix gaining momentum after last night's Emmy's, says Cantor
Netflix (NFLX) left last night's 67th Emmy Awards with four trophies and Amazon (AMZN) "a surprising" five, Cantor Fitzgerald analyst Youssef Squali points out in a research note to investors. Netflix's performance is "somewhat disappointing" relative to last year's seven emmys, but it's still a "notable performance" for an $8.99 per month service that started in 2012, Squali argues. The combined 46 nominations for Netflix and Amazon is a "clear indication" that over-the-top streaming services are a "growing threat to the establishment," Squali writes. The analyst views this phenomenon, coupled with solid reviews for Narcos, ongoing expansion throughout Asia and a recent price hike in major European markets as signs Netflix is seeing strong momentum into the second half of 2015. He reiterates a Buy rating on the stock with a $125 price target. Netflix is up 15c to $102.71 in late morning trading.
10:49 EDTAAPLGoPro falls after Barron's predicts 'dramatic' drop in share price
GoPro (GPRO) shares fell in morning trading after an article from Barron's argued that the company's share price may drop to as low as $25. WHAT'S NEW: Alexander Eule argued in a Barron's article that GoPro's stock price may see a "dramatic" slip of as much as 30% to $25 due to significant competitive pressure from Apple (AAPL), Sony (SNE) and others. Eule noted that the company's shares have crashed to a recent $35 after peaking at $98 in October 2014 and even called the mostly bullish analyst views on the camera maker's stock "wishful thinking." Additionally, Eule called the company's cameras a "one-product wonder" and compares them to BlackBerry (BBRY) smartphones and Palm digital organizers, which previously dominated their respective markets. The article adds that there is risk in being overly bearish on the company, since the "impressive" brand might become an acquisition target. WHAT'S NOTABLE: Last Wednesday, Citi analyst Jeremy David said that GoPro chief financial officer Jack Lazar confirmed at the bank's Global Tech Conference the week before that the Hero4 Session camera has been off to a slow start since its launch on July 12. David said that the recent selloff in the company's shares has been motivated by investor concerns about the Session. At the time, Citi cut its third quarter fiscal 2015 estimate for the company to $425M from $438M and fourth quarter estimate to $560M from $737M, $148M below consensus estimate at the time of $708M. David also said he was reducing estimates for the second half of fiscal 2015 and first quarter of fiscal 2016 as a result of downside from the Hero4 Session, but left estimates after 1Q16 unchanged, saying the long-term fundamentals of the company are "intact." The analyst added that his firm was "humbled" by the recent move in share price and acknowledged that GoPro is the "quintessential product cycle stock," though he said he remains bullish on the long-term prospects of the camera maker and reiterated a $90 price target. David argued that GoPro missing Q3 estimates and guiding below the consensus for Q4 is largely priced in. Separately, The Wall Street Journal said on September 13 that shares of GoPro were starting to look like a bargain after dropping 50% in a month. The company had a difficult time selling its Hero4 Session camera in July in the face of competition from older GoPro models, the publication added. PRICE ACTION: In morning trading, GoPro shares are down 5.15% to $33.34. OTHERS TO WATCH: Ambarella (AMBA), which supplies chips to GoPro, is down 3.7% to $68.81.
09:40 EDTNFLX, TSLA, TWTR, AAPLActive equity options trading on open
Active equity options trading on open: AAPL BAC ESV BABA FB NFLX TSLA TWTR GE GPRO JPM ONVO MU
09:14 EDTNFLXNetflix CEO congratulates HBO on Emmy dominance
Netflix (NFLX) CEO Reed Hastings tweeted out: "Congrats @HBO on supporting so much Emmy-winning talent. Your leadership of great television is inspiring." Time Warner's (TWX) HBO dominated the Emmy awards ceremony with 43 awards over all, including 29 Creative Emmys last week. Viacom's (VIA) Comedy Central, with four wins, was the network with the second-highest number of awards last night. Meanwhile, Hastings' won Netflix won four awards and Amazon (AMZN) earned its first-ever Emmy wins with two awards for its series "Transparent." Reference Link
08:40 EDTTSLATesla October volatility elevated at 78
Subscribe for More Information
08:31 EDTAAPLApple says iPhone 6s, iPhone 6s Plus to arrive on Friday, September 25
Apple announced iPhone 6s and iPhone 6s Plus will be available at 8:00 a.m. local time on Friday, September 25 at Apple's retail stores. Stores will have the new iPhones available for walk-in customers who are encouraged to arrive early. Both models will also be available on Friday from AT&T, Sprint, T-Mobile, Verizon Wireless, additional carriers and select Apple Authorized Resellers. Apple also announced the fastest iOS adoption ever, with more than 50 percent of devices already using iOS 9. Apple says "iPhone 6s and iPhone 6s Plus bring a powerful new dimension to iPhone's revolutionary Multi-Touch(TM) interface with 3D Touch, which senses how deeply you press the display, letting you do essential things more quickly and simply. The new iPhones introduce Live Photos, which bring still images to life, transforming instants frozen in time into unforgettable living memories. Live Photos, 3D Touch, 12-megapixel iSight camera, 5-megapixel FaceTime HD camera with Retina Flash and more are powered by the Apple-designed A9 chip, the most advanced chip ever in a smartphone, delivering faster performance and great battery life. iPhone 6s and iPhone 6s Plus are designed with the strongest glass on any smartphone and 7000 series aluminum, the same alloy used in the aerospace industry, in gorgeous metallic finishes that now include rose gold."
08:29 EDTMRKANI Pharmaceuticals to host conference call
Subscribe for More Information
08:22 EDTAAPLApple survey suggests strong iPhone demand, says Baird
Subscribe for More Information
08:06 EDTMRKMerck to present data on KEYTRUDA at European Cancer Congress
Merck announced that new data investigating the anti-tumor activity of KEYTRUDA across a broad range of advanced cancers will be presented at this year's European Cancer Congress in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts across nine difficult-to-treat cancers will be presented at this year's ECC - including four late-breaking oral presentations. First-time data looking at PD-L2 expression in multiple tumors to assess the potential value of this biomarker in patient responsiveness to anti PD-1 therapies will also be presented. With these and other presentations, data on the potential role of KEYTRUDA will have been presented in more than 17 different cancers. Studies accepted into this year's ECC program also include the investigation of KEYTRUDA monotherapy in anal cancer, biliary tract cancer, colorectal cancer, Merkel cell carcinoma, nasopharyngeal carcinoma, and non-small cell lung cancer, as well as a study evaluating KEYTRUDA in combination with another immunotherapy treatment in melanoma. KEYTRUDA, Merck's anti-PD-1 therapy, is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The KEYTRUDA clinical development program has rapidly expanded to encompass more than 30 tumor types in more than 130 clinical trials, of which more than 70 trials combine KEYTRUDA with other cancer treatments. Registration-enabling trials of KEYTRUDA monotherapy are currently enrolling patients in melanoma, NSCLC, head and neck cancer, bladder cancer, gastric cancer, colorectal cancer, and Hodgkin Lymphoma, with further trials in planning for other cancers.
07:43 EDTAAPLApple surveys indicate iPhone increasing high-end share, says Canaccord
Subscribe for More Information
07:19 EDTGOOGGoogle Class A price target raised to $847 from $720 at JMP Securities
Subscribe for More Information
06:34 EDTAAPLSamsung may be planning leasing program for Galaxy phones, Forbes reports
Samsung (SSNLF) is rumored to be planning to launch a leasing program for its Galaxy phones in the U.S., similar to the program Apple (AAPL) recently announced, Forbes reports, citing an industry executive with knowledge of Samsung's plans. According to the source, Samsung could launch the leasing program in the next few months. Apple's iPhone Upgrade Program encourages consumers to buy iPhones directly from the Apple Store instead of going through carriers, the publication notes. Publicly traded wireless carriers include AT&T (T), Verizon (VZ), Sprint (S) and T-Mobile US (TMUS). Reference Link
06:24 EDTGOOGEU's web rules won't discriminate against U.S. tech companies, WSJ reports
Subscribe for More Information
06:24 EDTAAPLFoxconn seeks to acquire Sharp's LCD business, Nikkei reports
Taiwan's Hon Hai Precision Industry, better known as Foxconn (HNHPF) has offered to buy Sharp's (SHCAY) struggling LCD business and plans to seek funding from Apple (AAPL), a key Sharp customer, The Nikkei reports. According to the report, Foxconn would take a majority stake in a LCD company spun off by Sharp, with Apple also making an investment. Reference Link
06:07 EDTAAPLApple hit by rare malware in China, Financial Times reports
Subscribe for More Information
06:07 EDTAAPLApple meets with regulators to discuss self-driving cars, Financial Times says
Subscribe for More Information
06:01 EDTGOOGGoogle holding event on September 29, The Verge reports
Google will hold its fall event on Tuesday, September 29, The Verge reports. According to the publication, Google is likely to introduce new Nexus smartphones -- one from LG and one from Huawei -- as well as an updated Chromecast. Reference Link
September 20, 2015
16:56 EDTMRKMerck says Phase 3 studies of bezlotoxumab for C. difficile met primary endpoint
Merck announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin for prevention of clostridium difficile infection recurrence, met their primary efficacy endpoint of reducing C. difficile recurrence through week 12 compared to placebo, when used in conjunction with standard of care antibiotics for the treatment of C. difficile. Based on the results, the company said it plans to submit new drug applications seeking regulatory approval of bezlotoxumab in the U.S., EU, and Canada in 2015. Results from the studies were presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting. Two global, Phase 3, double-blind studies were conducted to evaluate bezlotoxumab, either alone or in combination with actoxumab. The MODIFY I study enrolled 1452 patients at a median age of 65 years in 19 countries, and the MODIFY II study enrolled 1203 patients at a median age 67 years in 17 countries. In both MODIFY I and MODIFY II, the rate of C. difficile infection recurrence through week 12 was "significantly" lower in the bezlotoxumab arms -- 17.4% and 15.7% -- and the combination bezlotoxumab and actoxumab arms -- 15.9% and 14.9% -- compared to the placebo arms, which showed infection recurrence rates of 27.6% and 25.7%, respectively. In both studies, the rate of infection recurrence was lower in the bezlotoxumab arms compared to the placebo arms in patient subgroups known to be at high risk for recurrence, including patients with any prior episodes of C. difficile infection within the previous six months, patients infected with the BI/NAP1/027 strain, patients with severe infection, patients 65 years of age or older, and patients with compromised immunity. Treatment with the combination of bezlotoxumab and actoxumab did not provide added efficacy over bezlotoxumab alone. Furthermore, actoxumab alone provided no benefit in the prevention of C. difficile recurrence compared with placebo. Based on these results, bezlotoxumab alone was selected for the marketing authorization application.
14:46 EDTAAPLCompany split may not end troubles at Hewlett-Packard, Barron's says
Subscribe for More Information
12:49 EDTAAPLGoPro shares could fall another 30% to $25, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use